{"name":"Antengene Discovery Limited","slug":"antengene-discovery-limited","ticker":"","exchange":"","domain":"","description":"","hq":"","founded":0,"employees":"","ceo":"","sector":"","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[],"pipeline":[],"recentEvents":[],"realNews":[{"url":"https://news.google.com/rss/articles/CBMijwFBVV95cUxNM1QxOV9KUG9ocjNrdmRUeENSYjBKOFJNNUlUd0dEdy1HdkRycm80dS00X3Q5SDdDMXlGMXZwMlJlaHBJOUhldFJJd2ZaYnNsazhUQnlpZVFJVTZYQkxxNU9pX2ZaZlQ3QklvQ1NBZXpYcHM0SE1qNW1OWnlKSlFLTDN0UXZWdlpIWDdTOVd4UQ?oc=5","date":"2026-03-04","type":"deal","source":"The Pharma Letter","summary":"UCB inks license agreement with Antengene - The Pharma Letter","headline":"UCB inks license agreement with Antengene","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMihwJBVV95cUxPNF9YNzZfNFdvblZJeV9YWWViZVBLY1pxZlZ6LVZUVktXaGtwaXluejduNnVZNFhLay1lZmlXWnV3THJMNVMxNGpQczZnNTNhVEJlSk05dGxNeDlJV0VVR2l3bkVtZkFvZE5RLWE5VEQwMFBSSm5oeVcxMVBlTnVEMXZHTHRsX3ZfQkdMVkZEMXNxUi1CMm00bm5feER1aHZPXzZOeVY4cXpIeVZWR3cxUWtMQUpOWmpjNWZCdDJaUHdmYm1ROFZCQkcyNDA2WlY0bGN1R2hnOGNNQndvNzJQQmFBV2Nqb0RjOWYzbm1IWlVQRXdtV1JRQ1FGSXhwTnZXX0xTbi1jNA?oc=5","date":"2026-03-03","type":"deal","source":"PR Newswire","summary":"Antengene and UCB Enter Global License Agreement for ATG-201, a CD19/CD3 Bispecific T-Cell Engager for Autoimmune Diseases - PR Newswire","headline":"Antengene and UCB Enter Global License Agreement for ATG-201, a CD19/CD3 Bispecific T-Cell Engager for Autoimmune Diseas","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiywFBVV95cUxOX19Nb3lNZ3JUcGFOWEJuam1LMGlnUVdlOGxIQk9xM01ndnItTHRfUnhiZWhkZ0labUZ4cjFFNWFzVnFhVmYybVVaU2VNUWhSODdvTVFEenpmOW9EM0lfREl2dklxaUxSbDA0QktGUkZTWmVNcUZDQ2dEN2pCNkJFd0s5d2hLTGU2Tkx5NXNkSzI4N1JLUnpNa2kyaWFiMkczRlJMZkt2WWlCSEZiREZQYVdQTFU5aHhRYXIxbHlfTV9lUmczUk5XSWtEcw?oc=5","date":"2026-01-19","type":"trial","source":"BioPharma APAC","summary":"Antengene Showcases Next Phase Of Global Innovation At J P Morgan Healthcare Conference - BioPharma APAC","headline":"Antengene Showcases Next Phase Of Global Innovation At J P Morgan Healthcare Conference","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi9AFBVV95cUxPMzk1Q1NiYXRxNjBCUEEzY3NDRmU0ckJyakF3blRscU41cUdQSC11aTd4bmd3Q2tNTEs4eUVSRUhrSmMwSFVmcGtVazA5SHBSNXdfeXJfWUpMSTRYUFFfSXJ0eVk0NURnbjhVUzBFd3pIVG1VT3hqMWd6bG1wWC1pVWlXanNEMlZWT2k3WFJZMWZ0UzMzMFpVcHFKdmFoN3VFa3pnanhGbkdYQUFkdnFkazZqXzVnd04wdThVWVJCeFFQOTl2SUJXMFMyUGphYzVQOThHdEx6ZzhuM0ZPUHZwZWRZUFg3VTNETGRfYjY4Sm5sVHhQ?oc=5","date":"2026-01-15","type":"trial","source":"PR Newswire","summary":"Antengene Presents at JPM: Strong Clinical Data Update and Strategic Focus on Next-Generation ADCs and TCEs - PR Newswire","headline":"Antengene Presents at JPM: Strong Clinical Data Update and Strategic Focus on Next-Generation ADCs and TCEs","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiowJBVV95cUxPQkItWjlCTkNrSnNRY2tJX2VRQUFTMFBENzFwdUd0U05kUzhaVFBLVThNdFJTYnRKeS1Yd3BROFVoemNTYm9PTmpNLWxjckRWVXduSFIxUmpfSzV3Y2dhREZwZWZkUHRtOWVtZVBNTEkzRDZicWpCZExSVFduaFRZZTRqNWVrbG5HZXAtWTZQR05YbG5wbE5XRFNSMHVZMkYyQXJGa3pzdC1LNzdBeWdIRDNycHVVY3pvS3JFclgyd0RfSkczZ0oteFI2QnNFb1BrRGlEaExMSXNVRkNFRlhQRDRxVzViVXN3dndHNzMyMFhoaHhJVDQyODhCYXppYlpvZEc1Z3FvUkt6LVFJWndOUV80b1I3aThzUkVaUDY3QWwxU1k?oc=5","date":"2025-08-19","type":"pipeline","source":"PR Newswire","summary":"Antengene's ATG-022 (CLDN18.2 ADC) Granted Breakthrough Therapy Designation for the Treatment of Gastric/Gastroesophageal Junction Adenocarcinoma - PR Newswire","headline":"Antengene's ATG-022 (CLDN18.2 ADC) Granted Breakthrough Therapy Designation for the Treatment of Gastric/Gastroesophagea","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMipAFBVV95cUxOTF9Hc18zTXFwanViT3BqYUNDTUlzVWtmSU4xVVpESExZWTQ4bldKZnNTQ2R0eWlGMTJ2cEs5TE1QZnFyNHR2MXBQdllRTXNrMnJMMlFkSlh2cG56R2R3WmNMaVMzRFFsYmpUeVZEVkQ5YUlIa1VmMzJMZFR4dVBYeEN1XzZYUkFOVlZvQWQyTUx2YzJZQnc0MVc0MnJDd3NYWl9NSQ?oc=5","date":"2025-05-21","type":"deal","source":"Contract Pharma","summary":"Antengene & MSD Enter into a Global Clinical Collaboration - Contract Pharma","headline":"Antengene & MSD Enter into a Global Clinical Collaboration","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi5wFBVV95cUxPVk5DSjdXTGhMelpJZ09wejJVemhyRGh5U2ZzTFVOb0J4dGlCZjV6WlI1U2czS21RTjJsR1I3WFI1MzhUNjZYYzNMQ0JJeVpPR2UtQmpYSWl6Xzg3dlpVVnQ0S0pfaEp3Vy01eXpOZENfMXBia3Q1b0pqdzlJQWg0dERIN0haajZYSndKNFJRWWpTQ2UxX0dxTGNlQjdjUzZkaV9qenpLX2JtUWdXRk1acEVGMWZQWlc2SGdKLUp6dzJ0dS1xNnN0ZmE4UmFsSjhRTHJCcEMxaEg5U1VjNjBFRjlIQU5WSnc?oc=5","date":"2025-05-21","type":"deal","source":"BioPharma APAC","summary":"Antengene and MSD Enter Global Clinical Collaboration to Evaluate ATG-022 and KEYTRUDA® Combo in Solid Tumors - BioPharma APAC","headline":"Antengene and MSD Enter Global Clinical Collaboration to Evaluate ATG-022 and KEYTRUDA® Combo in Solid Tumors","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMinwJBVV95cUxQbGNyY0FoUE5aVnR3M1pEMFZkcC1MU1BTRDVuTnJOYXlMYmt5VUJfNXFFYjBidjZGazJCYXN2ZE5kU2poV1l6TWlHTlpQSE1WV1BpUFhvQjFUUFU4QTJTblljbWJLMy0zZUdJdE9VOVRUZnMzOFZGVklfU2N6UE9IVkhOczBsSkpWbHlSZnl0ek5GNjN2YVJrMlJaandxLTZDMHlHT09uYzhlU3NDaWpPUEVkeXBQYXU5enR5VVE3ejktNGNOY2xOZ1lSOGhWUkRKRlZ5ODdSZm9za3hnbmZfN0NhcEI3X2Rfbk4zLUdUUmVHVERuQ01kLTZEMlpxWGFKQUZCcEt3UmxIM1ZfS1N4TnU1WUxkdW91RlZHZU5RVQ?oc=5","date":"2025-05-20","type":"deal","source":"PR Newswire","summary":"Antengene Enters into a Global Clinical Collaboration with MSD to Evaluate ATG-022 (CLDN18.2 ADC) In Combination with KEYTRUDA® (pembrolizumab) - PR Newswire","headline":"Antengene Enters into a Global Clinical Collaboration with MSD to Evaluate ATG-022 (CLDN18.2 ADC) In Combination with KE","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMirgJBVV95cUxOVDdWa2VTajBPcmdTTWx0ODFZcllWZ3BUbUhiQzdWWnlKbmplMTdsNGpVVEVpazhIeXJaYU5lRnd5UXBiRzhDRE1WWjZNQ08tMWprQ3EtTmxMN3RIcXUxRFlITWpvaFlLb1VrMHRNR2RnNnBCSGdfTFNvbHc3ZmdsVFJXaUpCNkZ3ejNxQU1PQWxpdjJudllSZTlqVVhnczZYdVpXZ01YOXVPQ0lSSXdMNlFTUlJoRVExMXNERkFYalhaWDBvSURKQUFlVHVTQ01na05oOC1ZZ29TcW9PR19TTmcxS2dfc1VFaVBuS1R0ODZ2VXB3WUtYcEtXZzhya3NuU0NsZ0QtMl9wZ3QtUHJ2blFraEN5SDFhMXllOC1LWVVidUEwTkNWNHZ1RGI4dw?oc=5","date":"2023-08-10","type":"deal","source":"PR Newswire","summary":"Antengene Enters into Commercialization Partnership with Hansoh Pharma for First/Only-in-Class XPO1 Inhibitor XPOVIO®(selinexor) in the Mainland of China - PR Newswire","headline":"Antengene Enters into Commercialization Partnership with Hansoh Pharma for First/Only-in-Class XPO1 Inhibitor XPOVIO®(se","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMihwJBVV95cUxNelpQWjZXV0JRX1F3V1JrcDdBenFLTGNGZFpJRWNMT00zUmwteGZzb1I5aGVENkxmVGJoZk1zT0xoeDZFQk14VUpyci0xRlo3TTJjOENkUm4xUVlPVjA1SUdrU0ZsTFU4emxVMlhMWkpWYjNEWFk2OXAtZ0xQMVViNGdkb3hYRXpoeFpZbC02SzNnRlNUSDZCeXZVdXhlMDBXZ1drY0wtU084SlhKSkYxTjZQQ3NHenR0NW91N0NYRktTbmNwZm9GMll0bVE4NmRpand6N0IwZExSZW1uelZWQjA1QmRyRUZvUkk3SHZZd0RXQzhkeWVvVjF5b1RPX3EwZVdpOEJ5MA?oc=5","date":"2022-04-11","type":"pipeline","source":"enmobile.prnasia.com","summary":"Antengene Announces Publication of Five Posters at the 2022 American Association for Cancer Research (AACR) Annual Meeting - PR Newswire APAC - enmobile.prnasia.com","headline":"Antengene Announces Publication of Five Posters at the 2022 American Association for Cancer Research (AACR) Annual Meeti","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMixwJBVV95cUxORmRTWm9kUnA4SWR2MjhyMkFFSjU5cFhxSmtDQ0V1Vm9MaFk4cXVxZTlPbE9JNzdsSWlZOVFwck1CMjhmczZhbXlvdDVPVnNnV3hTWlFGMjZ6WnBrR0toczhjM25KT1dmdkgwcjFHb0V0LU01RkRoSXdXWmZ5akFDVHl5WW5aTnNPejY3b1QxbkJRUW1OX1RBeVp5ZzFzeENkMzZZdDNzWTRGcXhQNEZzY1pwS3k3b2l5czViREtnS0JLNndPNWJiYWpHN25BX3EzRmhfTTFQN2NUZzFuZ2M5SGhSMERTSGpUVHgyNm1JNERXN0VvaGZUMmVCUlEzMEZZY2pfRldxWVpzaWdlRUNnaDRselU3cEd4anp1LWxfdHdiSDFpYnVuMmtOYkZITHFkNU9ZU3VHdlAwblpkT2JzRXNYbjdnRXc?oc=5","date":"2022-03-01","type":"regulatory","source":"BioSpace","summary":"Antengene Announces XPOVIO® Regulatory Approval in Singapore for the Treatment of Relapsed and/or Refractory Multiple Myeloma and Relapsed/Refractory Diffuse Large B-Cell Lymphoma in Three Indications","headline":"Antengene Announces XPOVIO® Regulatory Approval in Singapore for the Treatment of Relapsed and/or Refractory Multiple My","sentiment":"positive"},{"url":"https://news.google.com/rss/articles/CBMiWkFVX3lxTE9YZzdOT1NpTEMxaHhhck92MVQ3bC1oNnE3cmdDbHRYaDRfMEYtTWd2QmNrb1BrdE1tVEp0ZnRrUkptWGhibUlOVU9lbG1zY0Y2OHpsbjFjcWxOdw?oc=5","date":"2020-11-19","type":"pipeline","source":"TradingView","summary":"6996 Stock Price and Chart — HKEX:6996 - TradingView","headline":"6996 Stock Price and Chart — HKEX:6996","sentiment":"neutral"}],"patents":[],"drugCount":0,"phaseCounts":{},"enrichmentLevel":2,"visitCount":1,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}